Desensitization and immune tolerance induction in children with severe factor IX deficiency; Inhibitors and adverse reactions to replacement therapy: A case-report and literature review

Italian Journal of Pediatrics

Volumn 41, Issue 1, 2015, Pages

  Bon, Andrea ^a   Morfini, Massimo ^b   Dini, Alessandro ^c   Mori, Francesca ^c   Barni, Simona ^c   Gianluca, Sottilotta ^d   De Martino, Maurizio ^c   Novembre, Elio ^c  

^a UNIVERSITY OF UDINE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

Author keywords

Children; Desensitization; Factor IX deficiency; Immune tolerance induction; Inhibitor antibodies

Indexed keywords

ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9; IMMUNOLOGIC FACTOR; RECOMBINANT PROTEIN;

ANTIBODY TITER; ARTICLE; BLEEDING; CASE REPORT; CHILD; CONTROLLED STUDY; COUGHING; CYANOSIS; DESENSITIZATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INFUSION; DRUG TOLERABILITY; FAINTNESS; HEMOPHILIA B; HUMAN; HYPEREMIA; IMMUNOLOGICAL TOLERANCE; MALE; PALLOR; PRESCHOOL CHILD; SIDE EFFECT; TREATMENT RESPONSE; IMMUNOLOGY;

CHILD, PRESCHOOL; DESENSITIZATION, IMMUNOLOGIC; FACTOR IX; HEMOPHILIA B; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC FACTORS; MALE; RECOMBINANT PROTEINS;

EID: 84924024436     PISSN: 17208424     EISSN: 18247288     Source Type: Journal    
DOI: 10.1186/s13052-015-0116-8     Document Type: Article

References (27)

1. Lusher J M, Chitlur M. Factor IX inhibitors in hemophilia B. In: Lee CA, Berntorp EE, Hoots W, editors. Textbook of Hemophilia. 2nd ed. Oxford: Blackwell Publishing Ltd; 2010.
2. Chitlur M, Warrier I, Rajpurkar M, Luscher JM. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006). Haemophilia. 2009;15:1027-31.
3. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet. 2003;361:1801-9.
4. Thorland EC, Drost JB, Lusher JM, Warrier I, Shapiro A, Koerper MA, et al. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: Complete gene deletions confer the highest risk. Haemophilia. 1999;5:101-5.
5. Astermark J. Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors. Haemophilia. 2006;12 suppl 6:8-14.
6. Astermark J. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia. Haemophilia. 2006;12 suppl 3:52-60.
7. High KA. Factor IX: molecular structure, epitopes, and mutations associated with inhibitor formation. Adv Exp Med Biol. 1995;386:79-86.
8. Belvini D, Salviato R, Radossi P, Pierbon F, Mori P, Castaldo G, et al. Molecular genotyping of the Italian cohort of patients with hemophilia B. Haematologica. 2005;90:635-42.
9. Warrier I: ITI in hemophilia B: Possibilities and problems. The international monitor on Hemophilia. 10 Year anniversary Issue, 2003: 20-23.
10. Warrier I, Ewenstein B, Koerper M, Shapiro A, Key N, DiMichele D, et al. FIX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol. 1997;19:23-7.
11. Warrier I. Management of hemophilia B patients with inhibitors and anaphylaxis. In: Varon D, Martinowitz U, Heim M, editors. Haemophilia and related disorders. Volume 4th ed. Oxford: Blackwell Science Ltd; 1998. p. 574-6.
12. Dioun AF, Ewenstein BM, Geha RS, Schneider LC. IgE-mediated allergy and desensitization to factor IX in hemophilia B. J Allergy Clin Immunol. 1998;102:113-7.
13. Sawamoto Y, Shima M, Yamamoto M, Kamisue S, Nakai H, Tanaka I, et al. Measurement of antifactor IX subclasses in hemophilia B patients who develop inhibitors with episodes of allergic reactions to factor IX concentrates. Thromb Res. 1996;83:279-86.
14. Vultaggio A, Maggi E, Matucci A. Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management. Curr Opin Allergy Clin Immunol. 2011;11:262-8.
15. Finkelman FD. Anaphylaxis: lessons from mouse model. J Allergy Clin Immunol. 2007;120:506-15.
16. Sumner MJ, Geldziler G, Pedersen M, Seremetis S. Treatment of acquired haemophilia with recombinant activated FVIIa: a critical appraisal. Haemophilia. 2007;13:452. 61.
17. Hedner U. Products used to treat hemophilia: recombinant factor VIIa. In: Lee CA, Berntorp EE, Hoots WK, editors. Textbook of Hemophilia. Vol 2nd ed. Oxford: Blackwell Publishing; 2007. p. 147-52.
18. Brackmann HH. Induced immunotolerance in factor VIII inhibitor patients. Prog Clin Biol Res. 1984;150:181-95.
19. DiMichele DM. Immune tolerance induction in haemophilia: evidence and the way forward. J Thromb Haemost. 2011;9 Suppl 1:216-25.
20. Barnes C, Brewin T, Ekert H. Induction of immune tolerance and suppression of anaphylaxis in a child with hemophilia B by simple plasmapheresis and antigen exposure: progress report. Hemophilia. 2001;7:437-8.
21. Shibata M, Shima M, Misu H, Okimoto Y, Giddings JC, Yoshioka A. Management of hemophilia B inhibitor patients with anaphylactic reactions to FIX concentrates. Haemophilia. 2003;9:269-71.
22. Alexander S, Hopewell S, Hunter S, Chouksey A. Rituximab and desensitization for a patient with severe factor IX deficiency, inhibitors, and history of anaphylaxis. J Pediatr Hematol Oncol. 2008;30(1):93-5.
23. Waters B, Lillicrap D. The molecular mechanisms of immunomodulation and tolerance induction to factor VIII. J Thromb Haemost. 2009;7:1446-56.
24. Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis. 2009;15:1264-75.
25. Ewenstein BM, Takemoto C, Warrier I, Lusher J, Said P, Eisele J, et al. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood. 1997;89:1115-6.
26. Dharnidharka VR, Takemoto C, Ewenstein BM, Rosen S, Harris HW. Membranous glomerulonephritis and nephrosis post factor IX infusions in hemophilia B. Pediatr Nephrol. 1998;12:654-7.
27. Warrier I. Factor IX inhibitors and anaphylaxis. In: Rodriguez-Merchan ED, Lee CA, editors. Inhibitors in patients with Haemophilia. Oxford: Blackwell Science; 2002. p. 87-91.